GH Research: This European Biotech Company Reports Full Year 2023 Financial Results And Business Updates
GH Research: This European Biotech Company Reports Full Year 2023 Financial Results And Business Updates
GH Research：这家欧洲生物技术公司报告了2023年全年财务业绩和业务更新
Nasdaq-listed, GH Research (NASDAQ:GHRS) is a clinical-stage biopharma business developing novel 5-MeO-DMT therapies as transformative treatment of psychiatric and neurological disorders.
在纳斯达克上市的GH Research（纳斯达克股票代码：GHRS）是一家临床阶段的生物制药企业，正在开发新的5-meo-DMT疗法，作为精神和神经系统疾病的变革性治疗方法。
Its reported yearly financial results show:
其报告的年度财务业绩显示：
Cash position of $ 222.7 million by December 31, 2023, an 11.5% decrease as compared to that held by December 31, 2022.
Yearly R&D expenses totaled $29.8 million, a 45% increase as compared to the $20.5 million spent in 2022.
Yearly G&A expenses totaled $11.4 million, a 12.8% increase as compared to the $10.1 million spent in 2022.
Yearly net loss of $35.6 million (or $0.68 loss per share), a 58% rise from the 2022 net loss ($22.5 million, or $0.43 loss per share.)
截至2023年12月31日，现金状况为2.227亿美元，与截至2022年12月31日的现金状况相比下降了11.5％。
每年的研发费用总额为2980万美元，与2022年的2,050万美元相比增长了45％。
每年的并购支出总额为1140万美元，与2022年的1,010万美元相比增长了12.8％。
年度净亏损3560万美元（合每股亏损0.68美元），较2022年的净亏损（2,250万美元，合每股亏损0.43美元）增长了58％。
Additional financial...
20...
登录免费看全文
登录/注册